ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0219

Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Abstract Number: 0220

Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies
Abstract Number: 0221

Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Abstract Number: 0222

tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
Abstract Number: 0223

Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)
Abstract Number: 0224

Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
Abstract Number: 0225

Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
Abstract Number: 0226

Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
Abstract Number: 0227

Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Abstract Number: 0228

Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Abstract Number: 0229

Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
Abstract Number: 0230

Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial
Abstract Number: 0231

Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset
Abstract Number: 0232

Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
Abstract Number: 0233

Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].